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Abstract:
Stimulation of the occipital nerves is becoming more widely accepted in the
treatment of occipital neuritis and migraine disorders. Presently, equipment available for
spinal cord stimulation is adapted for insertion into the subcutaneous space over the
occipital nerves. Many technical factors need to be reassessed to optimize the therapy.
We performed a retrospective review of patients implanted from 2003-2007 at a single
center. We aimed to analyze the rate of surgical complications related to implantation
technique. A total of 28 patients were present for analysis. Patients were followed up to
60 months with a mean follow up of 21 months. There is a 32% revision rate for
electrode migration or displacement, 3.6% removal rate for infection, and a 21% removal
rate for lack of efficacy. Although not well studied secondary to small patient
populations, this was consistent with a review of the literature which demonstrated a 1060% revision rate. Other factors such as anchoring strategy, strain relief, and battery
location were all considered in the analysis and will be presented. A major determination
was that use of a second incision with an additional strain relief loop had only a 10%
revision rate of the lead while those without this additional strain relief loop had a 62.5%
revision rate. Many technical factors need to be addressed for optimization of occipital
nerve stimulation.

Introduction:

The treatment of chronic neuropathic pain in the craniofacial region continues to
be a challenge. Peripheral nerve stimulation has been attempted to treat craniofacial pain
for these types of patients. Although the use of peripheral nerve stimulators is a not a
novel concept, its use in the craniofacial region is relatively recent.
Multiple studies have shown the effective treatment of occipital neuralgia with
stimulation of the occipital nerve (6,7,8). Slavin et al. have described benefits in 70% of
the patients treated for occipital neuralgia.(6) Similar results were reported by Melvin et
al, in which 91% of the patients treated for C2 mediated occipital headaches reported
reduction in medication use as well as 64% of the patients experienced reduction in the
number of headaches (7). Other studies have also shown the efficacy of occipital nerve
stimulation for the treatment of migraine headaches (2,9,10). Schwedt et al. reported that
9 out of 15 patients (60%) treated for various chronic headache syndromes experienced a
30% reduction in headache severity and frequency (2). In another study, 85% of patients
with transformed migraine showed a greater than 50% reduction in frequency or severity
of the headache after stimulation (9). Further studies are being carried out to further
investigate the effectiveness of occipital stimulation for other headache disorders (10).
Equipment designed for spinal cord stimulation equipment is used for
implantation into the occipital region over the distal branches of occipital nerves to
induce an anti-nocioceptive effect. Occipital nerve stimulation as such is susceptible to
the complications that have been described with the use of spinal cord stimulators. These
complications include, lead migration, infection, pain, as well as device failure (1). The
most common of these complications is lead migration and often requires surgical
intervention (1,13,14). In 1993, in a study by North et al. which described a 20 year
experience ,lead migration was found in 22% of patients although the percentage of
patients that needed surgical intervention was not disclosed. (12). In another review of
the literature by Ubbink et al., 14.8% of patients required surgical intervention due to
lead migration or fracture (13).
With occipital nerve stimulation, there has also been a significant lead migration
requiring subsequent surgical intervention. Slavin et al. have reported 10% patients
experiencing lead migration which required surgical intervention (6). Similarly, Melvin et
al have reported 9% lead migration (7). Popeney et al. described a slightly higher rate at
3/25 patients (12%) having spontaneous lead migration which required surgical
intervention. However, in a study of 15 patients done by TJ Schwedt et al, there was a
33% lead migration 6 months post implantation, 60% migration after 2 years, and 100%
migration after 3 years.(2). Due to a lack of studies with large sample size it is hard to
quantify the percentage of patients that will experience lead migration and subsequent
surgical intervention.
Another serious complication is infection at the surgical site. The rate of infection
has ranged from 2%-10% in patients who received implantable pain therapy devices such
as spinal cord stimulators (3,4,5). Finally other complications can occur with the device
such as electrical failure, loss of charge, or programming issues.
The purpose of this study is not to discuss the efficacy of occipital nerve
stimulators, but is to analyze the rate of surgical complications related to implantation
technique specific to occipital nerve stimulation and compare this to complication rates
observed in the literature for peripheral nerve stimulation.

Methods:
After attaining institutional review board approval, a retrospectively chart review was
performed. All patients who had undergone occipital nerve stimulation from 2003- 2007
were included in the review. 28 patients met criteria for inclusion within the study. Ages
ranged from 22-63 years with 25 female and 3 male patients. Average age of patients was
41 years. Table 1 further details the patient demographics. Follow up ranged from 6-60
months with a mean follow-up period of 21 months. The analysis was performed based
on surgical details, complications, and reports from repeated operations. Patient
satisfaction as well as efficacy of the stimulation was not analyzed.
Implantation
Device: The peripheral nerve system implanted consisted of an implantable pulse
generator, as well as a percutaneous lead with use of extensions. Equipment form three
manufacturers were used. These included Medtronic, Advanced Neuromodulation
Systems(ANS) and ABS. All subjects initially received 2 conventionally placeable
percutaneously wire leads with either 4 contacts or 8 contacts placed through a midline
incision between the base of the occiput and C2. The IPG utilized was either a 8 or 16
channel programmable device. Anchors provided by the specific manufacturer were used.
Trial:
All patients had received a pre- implantation trial. However, these trials were not all
standardized. Twenty patients received an outpatient trial over three to five days prior to
implantation. Eight patients had only an on table trial. All patients were implanted
within 4 weeks of their trial. Those implanted with ANS(16) or ABS(4) received a trial
prior to implantation while those with a Medtronic implant(8) had an on- table trial. All
patients reported greater than 50 percent of headache reduction during these trials.
Surgical Implantation:
Patients were implanted either under general anesthesia or under intravenous sedation
with local anesthesia. The patients were placed in a prone position if under general
anesthesia or positioned in the lateral position if done under IV sedation.
A midline 2cm incision was made at the level of C1 and an approximate 2cm
subcutaneous pocket was created above and visualizing the occipital cervical fascia. A
Touhy needle was advanced laterally on the skull from the midline incision in a trajectory
over the occipital nerve. If the patient were under general anesthesia, the trajectory was
determined by insonating the occipital artery aiming the Touhy needle across that region
(16, 17). If the patient were under sedation, awake testing was performed to test for
maximal stimulation of the occipital region during intra-operative testing. Multiple
repositions were potentially performed to achieve this. The needle was used to place the
lead. The lead was then secured via an anchor placed proximal to the electrode. The
anchor was secured to the fascia and to the electrode with two neurolon sutures. In every
case, a strain relief loop was tucked into the subcutaneous fascia after creating an area
with less tension.

The IPG was then placed via an incision in the buttocks, chest, or abdomen and
the location was determined based on the patient’s preference. Leads were tunneled to an
extension when needed. Later in the learning curve, a paraspinal incision was added and
an additional subcutaneous pocket was created in the region around C7- T1 where an
additional strain relief loop was placed and secured with a stitch. There was then further
tunneling to the IPG. Incisions were then closed in two layers. The patient were all taken
to the recovery room and subsequently discharged home on the same day.
Results:
Twenty-eight patients were included for evaluation. Follow up was 2-60 months with a
mean of 21 months. Follow up included office visits at 1 week, 1 month, 1 year, and 2
years with X-rays for evaluation as well as any additional needed office visits. Age of
patients ranged from 22-63 years with 25 female and 3 male patients. Average age of
patients was 41yo.

The most common adverse event was lead migration (Table1). This was observed in 7 of
the 28 patients and they were all females. In fact, there were a total of 13 revisions
surgeries in those 7 patients. This was observed over the continuum of the 60 month
follow up period demonstrating it to be a phenomenon seen well after the acute period of
implantation. There was a 26 week average time to revision with 54% requiring revision
within 8 weeks, 39% within 4 weeks and 31% within 2 weeks. All 13 lead migration
required surgical revision. It is of importance to note that only 3 of the observed lead
migrations (23% of the migrations) were secondary to documented traumas which lead to
the displacement of the leads. One of these was a facial trauma which caused
hyperextension of the neck and a broken lead. Another was a fall while standing into a
door causing flexion- rotation of the neck which caused displacement of the lead. While
the third was observed after a motor vehicle accident. In all patients treated for migration
the effectiveness of the stimulator was restored after revision and no residual side-effects
were noted.
Over time the surgical technique was modified to include an additional strain relief loop
placed via a second incision in the cervical-thoracic paraspinal region. Use of a second
incision with an additional strain relief loop had a 10% revision rate of the lead while
those without this additional strain relief loop had a 62.5% revision rate. The two
revisions (10%) noted with a second strain relief loop were also observed only after
documented trauma. The revision rate with those patients undergoing a second strain
relief loop excluding trauma would be 0% in the current review.

Initial electrode revision for migration was noted in 7 patients or 25% of total patients.
Five of these seven patients would undergo revision surgery again for electrode revision
(71%). Repeat revisions were only noted in those patients undergoing placement without
a second strain relief loop. Of note the two others not requiring a repeat revision were

patients who had initially been placed with a second strain relief loop but sustained a
trauma.
Other adverse events included infection. Five of the 28 patients (17.9%) developed signs
of an infection. Four of the 5 patients (14.3%) were successfully treated with PO
antibiotics with follow up in the office Two of the four patients treated with PO
antibiotics were at the IPG site (one abdomen, one buttock) while another was at the
cervical incision and the last was at the second incision lateral to C7-T1. One patient
(3.6%) required removal of the electrode and IPG with replacement in 2 months after a 6
week course of IV antibiotics. This patient had erosion of the wires through the skin of
her back.
In 6 patients (21%) the stimulator was removed for lack of efficacy. 5 of these 6 patients
felt that the stimulation was not effective while the sixth did not like the
sensation/parasthesias accompanying the stimulation. The degree of efficacy and patient
satisfaction with the stimulation is not evaluated in this study.
Two patients(7.1%) were noted to have persistent pain at the incisional sites. One patient
described pain in the cervical region which did not require surgical correction. The
anchors appeared to become palpable through the skin. The other patient (3.6%) was
noted to have pain at the battery site in the buttock. This patient even underwent
repositioning of the battery to the abdomen but still continues to have pain at the battery
site despite surgical re-exploration of that site. Incidentally, he is still continuing to use
his neural stimulation system to date.
Four patients were noted to have pain at their battery site. Three of these were in the
buttock from which there were 21 implants (14.2%) while one was in the chest for which
there were 5 implants (20%). Two of the three batteries placed in the buttock that had
pain required surgical revision. There were a total of 4 abdominal battery placements, of
which two were after revision from initial buttock placement. None of these patients
reported pain at their battery site.
Battery revision for migration was also noted. There was one migration in the chest (20%
of chest implants) as well as one migration in the buttock (4.8% of buttock implants).
Therefore there is a 7.1% battery migration rate noted across all patients and battery
placements. Migration was not noted in the four abdominal implants.
Of the remaining surgeries performed there was an IPG change in 4 patients (14%) for
end of life of the battery. There was also a revision of the IPG secondary to malfunction
of the battery in 1 patient (3.6%). This was observed after a fall in which the patient
landed on the battery. There was also a revision of the lead secondary to malfunction in 1
patient (3.6%).
In the 28 patients there were a total of 59 surgeries performed including those in
reference to the battery, while there was 41 surgeries total in reference to the leads. Each
patient underwent between 1 and 5 surgeries in the follow up period of 60 months.

Analyzing this data demonstrates that on average there was 2.1 surgeries per patient in a
60 month follow up period.
Discussion:
Occipital nerve stimulation is now being investigated for the treatment of chronic
headache syndromes (2, 7, 9, 10). Additionally, multiple previous studies have shown the
effective treatment of occipital neuralgia with peripheral stimulation of the occipital
nerve (6,7,8). The effectiveness of therapy will be dependent on patient population and
disease entity being treated and hopefully borne out in prospective clinical trials.
However, the effectiveness of the therapy is highly also influenced by its surgical
complications.
Occipital nerve stimulation can share some of the various complications that arise with
the use of spinal cord stimulators. These complications include lead migration, infection,
as well as device failure (1). The most common of these complications is lead migration
which has also been reported with spinal cord stimulators and this often requires surgical
intervention (1, 13, 14). The revision rate for peripheral nerve stimulation appears to be
higher than those rates observed for spinal cord stimulation (2, 6, 7, 12, 13). In a study of
15 patients with occipital nerve stimulation done by Schwedt et al, there was a 33% lead
migration 6 months post implantation, 60% migration after 2 years, and 100% migration
after 3 years.(2). Schwedt et al commented that surgical revision may be more common
after an adequate length of follow up. However, it is expected that most patients will have
lead migration requiring revision within 1 year of implantation. Oh et al found a 70%
revision rate for migration in occipital nerve stimulators within the first 6 weeks of
implantation (15). In this paper they believe that the use of percutaneous cylindrical
electrodes led to electrode migration secondary to anchor dislodgement from recurring
skull base spasm. Other papers have also commented on higher rates of migration with
the use of cylindrical electrodes in the high cervical region (9, 14). It was therefore felt
that use of a paddle style electrode was less likely to migrate secondary to the ability for
easier and more effective suturing or anchoring to the fascia or subcutaneous tissue (15).
In the current series, the most common adverse event was lead migration (Table1). These
were seen in 7 of the 28 patients followed for a total of 13 revisions within 41 surgeries
(32%). This was observed over the continuum of the 60 month follow up period
confirming that lead migration may be seen in most patients in the acute period but may
also occur over extended periods of follow up. It is of importance to note that 3 of the
observed lead migrations (23% of the migrations) were secondary to documented traumas
which lead to the displacement of the leads.
Methods of implantation and anchoring differ among surgeons. There is an evolution
over time that leads to changes in technique for anchoring as well as positioning of the
electrode. Important distinctions can be made on the choice of suturing to the
subcutaneous tissue versus the cervical fascia. Placement and methods of stress relief of
the leads can also effect the amount of lead migration sustained. Lastly the location and
placement of the IPG can change degree of strain on the electrode when considering
angle and direction of tunneling as well as distance from the electrode site.

In this series, the use of an additional strain relief loop through a separate incision
dramatically reduced the lead migration and revision rate. Patients with an additional
strain relief loop had only a 10% revision rate of the lead while those without this
additional strain relief loop had a 62.5% revision rate. Furthermore, the two revisions
(10%) noted with a second strain relief loop were also observed after a documented
trauma leading to the assumption that without associated trauma the revision rate would
be much lower.
It has been observed that there is less migration rates when using a midline incision as
oppose to a lateral incision (7). A midline incision dictates the use of two electrodes if
there is a need for bilateral stimulation. A single electrode can be used to span both
occipital nerves if a lateral incision is utilized. However it is felt that use of the midline
incision will allow more effective placement, ease of placement, and a greater ability to
anchor the electrode in a position that allows minimal migration, if any. Use of two
electrodes will also allow a greater area of coverage that cannot be obtained via a single
electrode that spans both occipital nerves.
Some patients were noted to have pain at their battery site. The majority of these were
noted with placement in the buttock. Two of the three batteries placed in the buttock that
had pain required surgical revision (7.1% total or 9.5% of buttock). There were a total of
4 abdominal battery placements, of which two were after revision from initial buttock
placement. None of these patients reported pain at their battery site. Although a small
number this suggests that patients tolerate placement of the IPG in the abdomen over the
buttock. It did not appear in our study to affect migration or revision rates. The drawback
to abdominal placement of the IPG is that it necessitates placement in the lateral position
in the operating room as oppose to prone when undergoing buttock placement.
Each patient underwent between 1 and 5 surgeries in the follow up period of 60 months.
Analyzing this data demonstrates that on average there was 2.1 surgeries per patient in a
60 month follow up period. One potential area of improvement is the type of equipment.
PNS systems are usually modified forms of spinal cord stimulation equipment. Although
there is interchangeability among the two it has become more evident that use of this
equipment has different rates of migration between use as a PNS and a SCS. It is
therefore feasible that with new equipment and technology we can limit the lead
migration rate by designing systems that are more specific to PNS. More specifically
stimulation in the cervical region leads to cervical tension as well as skull base spasm that
is not seen in other sites of PNS and this has to be taken into account when considering
causes of anchor dislodgement.
Another serious complication is infection at the surgical site. Historically, the rate of
infection has ranged from 2%-10% in patients who received implantable pain therapy
devices such as spinal cord stimulators (3,4,5). Our data showed a 3.6% removal rate for
infection and 17.9% overall rate of infection. 4 of the 5 patients (14.3%) were
successfully treated with oral antibiotics with follow up in the office. Two of the four
patients treated with oral antibiotics were at the IPG site while another was at the cervical

incision and the last was at the second incision lateral to C7-T1. There did not seem to be
a common factor, such as location of battery or placement of leads that lead to infection.
This is consistent with published data and seems to be interchangeable among SCS and
PNS.
Conclusion:
The rate of surgical revision with occipital nerve stimulators remains high. This may be
largely a factor of the differences in surgical techniques. A paddle style electrode
implanted via a midline incision may be effective in lowering this rate. Additionally,
better anchoring to the cervical fascia and the use of an second strain relief loop at the
cervical-thoracic junction may overcome the cervical tension imposed on the electrodes.
A consensus statement among implanting physicians critically analyzing the factors in
surgical technique to minimize complications is due. Overtime if there is not a change in
this rate of revision it will be interesting to evaluate if the effectiveness of occipital nerve
stimulation as a treatment modality for various syndromes out weights the multiple
surgeries required to maintain its sustainability. Finally, hardware related pain requiring
re-operation will also need to be addressed by the manufacturers.

Table 1a: Incidence of Adverse Events
Adverse Event
Lead Migration
Lead Migration secondary to
Trauma
Battery Migration
Infection-PO antibiotics
Infection-IV antibiotics
Lack Of Efficacy
Malfunction(Lead)
Malfunction(Battery)
EOL battery

Number of Patients
7 patients/13
revisions
3
2
4
1
6
1
1
4

Surgical Revision
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes

Rate of
Revision
32%
23% of
migrations
7.1%
14.3%
3.6%
21%
3.6%
3.6%
14%

Table 1b: Breakdown of Lead Migrations
Number of
Patients(First Revision)

Total Patients
Total Lead
Revisions
Patients with
Strain Relief
Loop
Strain relief loop
patients with lead
migration
Patients without
Strain Relief
Loop
Without strain
relief loop
patients with lead
migration

Percentage

Number of Patients
Requiring Repeat
Revisions after First

Percentage

28

100%

5

17.9%

7

25%

5 patients(6 revisions)

71%

20

71.5%

0

0%

2- (Both included
trauma)

10% (7.1% of
total patients)

0

0%

8

28.5%

5

71%

5

62.5% (17.9%
of total
patients)

6 revisions

85%

Table 1c: Other Events
Number
Buttock IPG Placement
Chest IPG Placement
Abdomen IPG
Placement

Percentage
21
5

75%
17.9%

2 initial/4 total

7.1%

Pain at IPG(Total)

4

14.3%

Pain at IPG(Buttock)

3

19.0%

Pain at IPG(Chest)

1

20.0%

Pain at IPG(Abdomen)

4

0.0%

Battery Revision for
Pain(Total)

2

7.1% of total

Battery Revision for
Pain(Buttock)

2

9.5% of Buttock
placement

1

3.6%

1

3.6%

Pain at Electrode
Electrode Revision For
Pain(at buttock incision)

Table 2: Demographics
Total Number of Patients
Year of Implant
Gender
Mean Age(range)
Average Follow up(range)
Average Number of
Surgeries(total)

28, ANS(16) Medtronic(8) ABS(4)
2003- 2007
25 Female, 3 Male
41years (22-63years)
21 months (6-60 months)
2.1 (59)
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